دورية أكاديمية
Comprehensive genomic profiling of ESR1, PIK3CA, AKT1, and PTEN in HR(+)HER2(-) metastatic breast cancer: prevalence along treatment course and predictive value for endocrine therapy resistance in real-world practice.
| العنوان: | Comprehensive genomic profiling of ESR1, PIK3CA, AKT1, and PTEN in HR(+)HER2(-) metastatic breast cancer: prevalence along treatment course and predictive value for endocrine therapy resistance in real-world practice. |
|---|---|
| المؤلفون: | Bhave, Manali A, Quintanilha, Julia C F, Tukachinsky, Hanna, Li, Gerald, Scott, Takara, Ross, Jeffrey S, Pasquina, Lincoln, Huang, Richard S P, McArthur, Heather, Levy, Mia A, Graf, Ryon P, Kalinsky, Kevin |
| المصدر: | Breast Cancer Res Treat ; ISSN:1573-7217 |
| بيانات النشر: | Springer |
| سنة النشر: | 2024 |
| المجموعة: | PubMed Central (PMC) |
| مصطلحات موضوعية: | AKT inhibitor, ESR1, Genomic sequencing, HR(+)HER2(−), Metastatic breast cancer |
| الوصف: | The treatment landscape for HR(+)HER2(-) metastatic breast cancer (MBC) is evolving for patients with ESR1 mutations (mut) and PI3K/AKT pathway genomic alterations (GA). We sought to inform clinical utility for comprehensive genomic profiling (CGP) using tissue (TBx) and liquid biopsies (LBx) in HR(+)HER2(-) MBC. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| العلاقة: | https://doi.org/10.1007/s10549-024-07376-wTest; https://pubmed.ncbi.nlm.nih.gov/38872062Test |
| DOI: | 10.1007/s10549-024-07376-w |
| الإتاحة: | https://doi.org/10.1007/s10549-024-07376-wTest https://pubmed.ncbi.nlm.nih.gov/38872062Test |
| حقوق: | © 2024. The Author(s). |
| رقم الانضمام: | edsbas.B05F74DC |
| قاعدة البيانات: | BASE |
| DOI: | 10.1007/s10549-024-07376-w |
|---|